Danaher promotes Julie Sawyer Montgomery to CEO
The executive has led Danaher’s diagnostics business, where she helped triple operating profit during her tenure and oversaw the recent acquisition of Masimo.
The executive has led Danaher’s diagnostics business, where she helped triple operating profit during her tenure and oversaw the recent acquisition of Masimo.
The anti-TL1A antibody from Merck’s 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside second-quarter earnings.
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss Read More »
Half a year after major cuts to the Affordable Care Act exchanges went into effect, hospitals say more patients are going uninsured. That’s starting to drag their finances, for-profit hospitals say.
Hospitals say they’re feeling the pinch as more patients lose insurance Read More »
Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine Read More »
The additional cuts, which will primarily occur between 2027 and 2029, will cost some $6 billion as the pharma tries to ride out a post-COVID headache while facing stiff patent headwinds for major products like the blood thinner Eliquis.
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure Read More »
While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be more mixed.
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger Read More »
Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of the AstraZeneca agreement were not disclosed.
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab Read More »
Positive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said on the company’s second quarter earnings call.
Vertex unfazed by competitive IgAN space as FDA verdict looms Read More »
Así aprende una fábrica a escuchar sus propias máquinas El Internet de las Cosas ya forma parte de tu vida cotidiana cuando un reloj mide tu pulso o un termostato regula la calefacción. Dentro de una fábrica, esta tecnología adquiere otra …
La fórmula es la más famosa del planeta: H2O. Dos átomos de hidrógeno y uno de oxígeno. Nos la enseñan en el colegio y la asumimos como una verdad absoluta, simple y estática. Sin embargo, si pudiéramos encogernos a la escala nanométrica …
Por qué la estructura íntima del agua líquida sigue desconcertando a la ciencia Read More »